$ONNVF News
Last published 2mo ago
- 2mo agoONNVFIBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations Ltd.GlobeNewswireDisseminated on behalf of Onco-Innovations Ltd., may include paid advertisements. AUSTIN, Texas, Sept. 10, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting
- 4mo agoONNVFNetworkNewsAudio Announces Audio Press Release (APR) Discussing the Development of PNKP Inhibitors in Oncology Drug DevelopmentGlobeNewswireAUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled "Next-Generation DNA Repair Therapies Open New Frontiers in Oncology," featuring
- 4mo agoONNVFOnco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Leading Out in Developing Fresh Wave of Inhibitor ClassesGlobeNewswireNEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB:ONNVF) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands
- 4mo agoONNVFMRKPFEGSK+1Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging MarketGlobeNewswireAUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Oncology research is moving through one of its most active stretches in years. DNA Damage Response ("DDR") inhibitors, a category
- 4mo agoONNVFOnco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Advancing Nanoparticle-Encapsulated PNKP Inhibitor in Oncology SpaceGlobeNewswireNEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB:ONNVF) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands
- 4mo agoONNVFAZNAPREBOLD+1Next-Generation DNA Repair Therapies Open New Frontiers in OncologyGlobeNewswireAUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which